Asymmetric dimethylarginine predicts appropriate implantable cardioverterdefibrillator intervention in patients with left ventricular dysfunction

Europace

Volumn 13, Issue 10, 2011, Pages 1428-1435

  Lehmann, H Immo ^a   Goette, Andreas ^b   Martens Lobenhoffer, Jens ^a   Hammwhner, Matthias ^b   Rhl, Friedrich Wilhelm ^a   Bukowska, Alicja ^a   Ghanem, Ali ^a   Klein, Helmut U ^c   Bode Bger, Stefanie M ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b St Vincenz Hospital   (Germany)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

ADMA; Arg ADMA ratio; ICD intervention; Risk marker for SCD

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; ARGININE DERIVATIVE; BIOLOGICAL MARKER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DEFIBRILLATOR; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC CARDIOMYOPATHY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; DEFIBRILLATORS, IMPLANTABLE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80053417109     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur171     Document Type: Article

References (47)

1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40. (Pubitemid 26428217)
2. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. (Pubitemid 34984635)
4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. (Pubitemid 40110811)
5. Daubert JP, Zareba W, Hall WJ, Schuger C, Corsello A, Leon AR et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006;47:98-107. (Pubitemid 43005171)
6. Chow T, Kereiakes DJ, Onufer J, Woelfel A, Gursoy S, Peterson BJ et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol 2008;52:1607-15.
7. Dhar R, Alsheikh-Ali AA, Estes NAM, Moss AJ, Zareba W, Daubert JP et al. Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm 2008;5:807-13.
8. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339: 572-5.
9. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-64. (Pubitemid 30353888)
10. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7. (Pubitemid 28509278)
11. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3. (Pubitemid 33043860)
12. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-6. (Pubitemid 29120084)
13. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL et al. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 1998;37:667-75. (Pubitemid 28231161)
14. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 2003;18:177-82. (Pubitemid 37258670)
15. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-30. (Pubitemid 28273149)
16. Kielstein JT, Bode-Böger SM, Klein G, Graf S, Haller H, Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 2003;33:370-5. (Pubitemid 36583703)
17. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 2008;29: 2506-13.
18. Nijveldt RJ, Teerlink T, van der Hoven B, Siroen MPC, Kuik DJ, Rauwerda JA et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003;22:23-30. (Pubitemid 36193177)
19. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117. (Pubitemid 34094901)
20. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-2128. (Pubitemid 34094905)
21. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53:273-83. (Pubitemid 46338272)
22. Böger RH, Sullivan LM, Schwedhelm E,Wang TJ, Maas R, Benjamin EJ et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-600.
23. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84: 1589-96.
24. Teerlink JR, Clozel M, Fischli W, Clozel JP. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. J Am Coll Cardiol 1993;22:615-20. (Pubitemid 23214581)
25. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005;111:310-4. (Pubitemid 40165337)
26. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-346. (Pubitemid 44382683)
27. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-93.
28. Tsikas D. Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem 2000;72:4064-72.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
30. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20(Suppl. 12): S60-2. (Pubitemid 23014109)
31. Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988;153:1251-6.
32. Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007;114: 295-306. (Pubitemid 46843253)
33. Ardigo D, Stüehlinger M, Franzini L, Valtueña S, Piatti PM, Pachinger O et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 2007;37:263-9. (Pubitemid 46439414)
34. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:772-9. (Pubitemid 20090372)
35. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005;25:1174-9. (Pubitemid 40776605)
36. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002;62:339-45. (Pubitemid 34754080)
37. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994;89:2070-8. (Pubitemid 24142783)
38. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothelial control of left ventricular function in humans. Circulation 1995;92:2119-26.
39. Bronzwaer JGF, Heymes C, Visser CA, Paulus WJ. Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2003;284:H10-6. (Pubitemid 36076264)
40. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001;104:1286-91. (Pubitemid 32848119)
41. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998;32:273-9. (Pubitemid 28376484)
42. Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006;17: 1128-34.
43. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 2006;21:2446-51. (Pubitemid 44644516)
44. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989;264:10205-9. (Pubitemid 19159295)
45. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG,NG- dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995;117:237-8.
46. Zoccali C, Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens 2006;15: 314-320.
47. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:2039-44.